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Clinically applicable GABA receptor 
positive allosteric modulators 
promote ß-cell replication
Jide Tian, Hoa Dang, Blake Middleton & Daniel L. Kaufman
A key goal of diabetes research is to develop treatments to safely promote human ß-cell replication. 
It has recently become appreciated that activation of γ-aminobutyric acid receptors (GABA-Rs) on 
ß-cells can promote their survival and replication. A number of positive allosteric modulators (PAMs) 
that enhance GABA’s actions on neuronal GABAA-Rs are in clinical use. Repurposing these GABAA-R 
PAMs to help treat diabetes is theoretically appealing because of their safety and potential to enhance 
the ability of GABA, secreted from ß-cells, or exogenously administered, to promote ß-cell replication 
and survival. Here, we show that clinically applicable GABAA-R PAMs can increase significantly INS-1 
ß-cell replication, which is enhanced by exogenous GABA application. Furthermore, a GABAA-R PAM 
promoted human islet cell replication in vitro. This effect was abrogated by a GABAA-R antagonist. The 
combination of a PAM and low levels of exogenous GABA further increased human islet cell replication. 
These findings suggest that PAMs may potentiate the actions of GABA secreted by islet ß-cells on 
GABAA-Rs and provide a new class of drugs for diabetes treatment. Finally, our findings may explain a 
past clinical observation of a GABAA-R PAM reducing HbA1c levels in diabetic patients.
New therapeutic approaches are needed to safely promote ß-cell replication and increase ß-cell mass in indi-
viduals with type 1 and 2 diabetes (T1D and T2D). Rodent and human ß-cells have been long known to express 
the GABA synthetic enzyme glutamic acid decarboxylase (GAD), as well as GABAA-Rs and GABAB-Rs1. Recent 
studies have shown that the activation of ß-cell GABAA-Rs and GABAB-Rs can promote their survival, replica-
tion and mass2–6. Moreover, long-term GABA treatment can promote α-cell transdifferentiation into ß-cells by 
activation of GABAA-R7.
GABAA-R PAMs enhance the action of GABA. They do not bind to the GABA-binding site, but rather else-
where on GABAA-Rs. While they do not have agonist function to open the GABAA-R chloride channel, they 
increase in Cl− conductance when GABA is bound to the receptor8. Because GABA has little to no ability to pass 
through the blood brain barrier (BBB), BBB-permeable GABAA-R PAMs, such as the benzodiazepines, have been 
used to enhance the action of GABA secreted by neurons in the central nervous system (CNS) in order to treat 
CNS disorders such as seizures, insomnia, and anxiety. It is an open question whether these GABAA-R PAMs can 
be repurposed to increase the capacity of ß-cell-secreted GABA to promote ß-cell mitogenesis.
In the current study, we first assessed whether the rat ß-cell cell line INS-1 expressed the GABAA-R subunits 
that confer sensitivity to benzodiazepines and whether they were capable of synthesizing GABA. We then assessed 
the ability of clinically-applicable GABAA-Rs PAMs to promote the replication of rat INS-1 ß-cells. Specifically, 
we tested alprazolam (Xanax), midazolam, and clonazepam, which represent different classes of benzodiazepines 
(triazolo, imidazo, 7-nitro and 2-keto compounds, respectively). Alprazolam has been widely used for treating 
anxiety since the early 1980’s and nearly 50 million prescriptions are written annually for this medication. It is safe 
for long-term use when used as directed9, 10. In addition, we tested AP3, a newly developed non-benzodiazepine 
GABAA-R PAM. AP3 does not pass through the BBB and its structure is shown in Fig. 1. We then examined the 
effect of alprazolam, with, or without, exogenous GABA, on human islet cell replication in vitro. Our results using 
INS-1 cells and human islets indicated that treatment with a PAM alone, and to a greater extent the combination 
of a low dose of a PAM and exogenous GABA, significantly increased INS-1 ß-cell proliferation and human islet 
cell replication. This proof-of-principle study suggests that GABAA-R PAMs may be a new class of drugs to aid 
in diabetes treatment.
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Results
INS-1 cells express benzodiazepine-binding GABAA-R subunits. GABA can enhance INS-1 cell 
proliferation3, but it is unknown whether INS-1 cells express the GABAA-subunits that are sensitive to benzo-
diazepines. Publically accessible profiles of INS-1 cell gene expression are inconsistent in terms of the presence 
or absence of various GABAA-R subunit transcripts, perhaps due to their low level of expression. We therefore 
tested INS-1 cell RNA for the presence of transcripts which encode the GABAA-R subunits that confer sensitivity 
to benzodiazepines (α1, α2, α3, and α5)11, 12 using quantitative real-time PCR (qPCR). We detected α1, α3, and α5 
transcripts as well as ß1, γ1, γ2, γ3 subunits (data not shown), indicating that INS-1 cells may express GABAA-Rs 
that are sensitive to benzodiazepines.
INS-1 cells synthesize GABA at low levels. ß-cells express GAD and secrete GABA, which regulates islet 
ß-cell and α-cell function in an autocrine or paracrine fashion1, 13. Whether INS-1 cells also synthesize GABA is 
unknown. We therefore examined GAD enzymatic activity in INS-1 cells, human islets and mouse brains, as well 
as control 293 T cells. We found that the levels of GAD activity in INS-1 cells were considerably lower than that 
in human islets, which in turn were lower than that in mouse brains (Fig. 2A). Nonetheless, the levels of GAD 
activity in INS-1 cells were consistently about 2-fold higher than that of negative control 293 T cells, suggesting 
that INS-1 cells are capable of producing a low level of GABA.
GABAA-Rs PAMs enhance INS-1 cell proliferation in vitro. Given that INS-1 cells express benzodi-
azepine sensitive GABAA-R subunits and have the capacity to synthesize GABA, we tested whether clinically 
applicable GABAA-R PAMs could enhance their proliferation. INS-1 cells were treated with, or without, different 
concentrations of each PAM and their proliferation was determined by 3H-thymidine incorporation. Treatment 
with alprazolam or midazolam at 10 or/and 100 nM, but not with clonazepam or AP-3, significantly stimulated 
proliferation of INS-1 cells (Fig. 2B). Hence, some GABAA-R PAMs enhanced endogenous GABA-promoted 
proliferation of INS-1 cells in vitro.
PAMs enhance GABA-stimulated INS-1 cell proliferation. Next, we examined the impact of the com-
bination of exogenous GABA and a PAM on the proliferation of INS-1 cells. We found that treatment with GABA 
(alone) at 0.03–0.3 mM increased proliferation of INS-1 cells (Fig. 2C–F), consistent with a previous report3. 
While treatment with 0.01 mM GABA did not significantly increase INS-1 proliferation (Fig. 2C–F), treatment 
with the same dose of GABA in the presence of 30 or 100 nM alprazolam significantly increased INS-1 cell pro-
liferation, which was significantly higher than that of alprazolam alone or even a 10-fold higher concentration of 
GABA alone (0.1 mM, Fig. 2C). However, alprazolam had less ability to enhance INS-1 cell proliferation induced 
by a high concentration of GABA (0.1 or 0.3 mM), perhaps because high concentrations of GABA already induced 
maximal GABAA-R responses. In a similar fashion, treatment with low doses of midazolam, clonazepam, or AP-3 
enhanced GABA-stimulated INS-1 cell proliferation (Fig. 2D–F). Moreover, similar patterns of PAM-enhanced 
exogenous GABA-stimulated INS-1 cell proliferation were detected using MTT assays (Fig. S1). Thus, GABAA-R 
PAMs can potentiate GABA-induced ß-cell proliferation in vitro.
GABAA-R PAMs promote INS-1 cell proliferation independent of the mitochondrial transloca-
tor protein (TSPO). Some benzodiazepines bind to the mitochondrial translocator protein (TSPO), which 
was previously referred to as a “peripheral benzodiazepine receptor”. Alprazolam does not bind to TSPO14. To 
test whether midazolam and clonazepam may enhance INS-1 cell proliferation through binding to the TSPO, 
INS-1 cells were treated with, or without, the TSPO inhibitor PK11195 and stimulated with 0.3 mM GABA and 
100 nM midazolam or clonazepam for 48 h. Treatment reating prowith PK1119 did not significantly affect the 
ability of GABA and the tested benzodiazepines to enhance INS-1 cell replication (Fig. 2G), indicating that PAMs 
enhanced GABA-stimulated proliferation of INS-1 cells independent of TSPO.
Alprazolam enhances the ability of endogenous GABA to promote human islet cell replication 
in vitro. We next tested whether a PAM could enhance human islet cell replication. We focused on testing 
alprazolam because of its safety record9, 10 and the finding that alprazolam treatment reduced HbA1c in diabetic 
patients15. Human islets were treated with, or without, a dose range of alprazolam and the islet cell proliferation 
was determined by 3H-thymidine incorporation. We found that low concentrations of alprazolam promoted sig-
nificantly human islet cell proliferation (Fig. 3). Alprazolam’s pro-mitotic effects were abrogated by the presence 
of the GABAA-R antagonist bicuculline16 (Fig. 4) or the Ca2+ channel blocker nifedipine (1 µM, data not shown). 
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Figure 1. The structure of AP-3.
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Figure 2. (A) GAD enzymatic activity in INS-1 cells. The GAD enzymatic activity within homogenates was 
assessed using a standard CO2 trapping assay as described in Methods. Data shown are mean CPM + /− SEM 
from a representative assay from three experiments. (B) Effect of PAMs on INS-1 cell proliferation. INS-1 cells 
were cultured with the indicated PAM at a dose range of 10−9 to 10−6 M and assessed for their proliferation. 
Data shown are the average rate of proliferation relative to that of cultures with media alone (designated as 1). 
INS-1 cells were treated with alprazolam (C), midazolam (D), clonazepam (E), or AP-3 (F) at the indicated 
concentrations along with a dose range of GABA. Control cultures were incubated with GABA alone at the 
indicated concentration (solid lines). ††††p < 0.001 versus control cultures with medium alone. *p < 0.05, 
**p < 0.01, ***p < 0.001 versus cultures with the same dose of GABA, determined by Student T test. G) INS-1 
cells were cultured with GABA (0.3 mM) and midazolam or clonazepam (100 nM) with, or without, the TSPO 
inhibitor PK11195 (1 µM) for 48 hrs.
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Figure 3. Alprazolam enhances human islet cell replication. Fresh human islets were treated in triplicate with 
the indicated dosage of GABA, together with, or without, the indicated PAM as described in Methods. Data 
shown are the average rate of proliferation relative to that of cultures with medium alone (designated as 1). 
N = three independent studies. *p < 0.05, determined by Student T test.
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These observations are consistent with the notion that this PAM enhances GABAA-R-mediated activation of the 
PI3K/Akt signaling to enhance human islet cell proliferation3.
The combination of alprazolam and GABA has enhanced ability to promote human islet cell 
replication at low dosage in vitro. Finally, we examined whether alprazolam could potentiate the ability 
of exogenous GABA to promote human islet cell replication in vitro. Human islets were treated with, or without, 
different concentrations of GABA in the presence or absence of 100 nM alprazolam. We found that GABA (alone) 
at 0.3-3 mM, but not a lower dose, significantly enhanced human islet cell proliferation in a dose-dependent 
manner (Fig. 5). Co-treatment with alprazolam and GABA significantly increased human islet cell proliferation 
relative to the corresponding GABA (alone) doses (Fig. 5). Notably, while treatment with 0.03 mM GABA did not 
significantly enhance human islet cell proliferation, treatment with the same dose of GABA together with alpra-
zolam significantly increased human islet cell proliferation. To achieve a similar level of proliferation using GABA 
alone required a 10-fold higher level of GABA (0.3 mM, Fig. 5). Thus, alprazolam greatly potentiated the effect of 
exogenous GABA, reducing the level of GABA needed to induce human islet cell proliferation.
Discussion
GABA-R activation can protect ß-cells from apoptosis and promote their replication2–6. Oral GABA treatment 
increases human ß-cell replication several fold, typically from less than 1% to about 2–3% of adult human ß-cells 
in islet xenografts4, 6, which is similar to the maximum level of ß-cell replication that takes place shortly after birth. 
The ability of GABA treatment to promote ß-cell replication did not attenuate over the course of five weeks and 
led to increased ß-cell mass and function in human islet xenografts6. Additionally, long-term GABA treatment 
promotes the transdifferentiation of α-cells into ß-cells7. Accordingly, repurposing clinically applicable GABAA-R 
PAMs to enhance the activity of GABA secreted by ß-cells, or the effect of exogenous GABA, is an attractive 
new strategy for helping to treat diabetes. Moreover, combination treatment with GABA and a GABAA-R PAM 
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Figure 4. Treatment with bicuculline ablates the ability of alprazolam to enhance islet cell replication. Human 
islets were incubated with alprazolam (100 nM) together with a standard dose range of bicuculline (0–50 uM). 
Data shown are the average rate of proliferation relative to that of cultures with medium alone (designated as 1).
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Figure 5. Alprazolam enhances GABA’s ability to promote human islet cell replication. Human islets were 
incubated with a dose range of GABA together with alprazolam (100 ng/ml) for 4 days in the presence of 3H 
thymidine. Data shown are the average rate of proliferation relative to that of cultures with medium alone 
(designated as 1) in a representative study. N = two independent studies with triplicate cultures. The results were 
very similar in both studies. ††p < 0.01 and †††p < 0.001for GABA, or GABA + alprazolam vs. control medium 
alone; *p < 0.05 and ***P < 0.01 for GABA + alprazolam vs. GABA alone, determined by Student T-test.
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may simultaneously inhibit pathogenic autoimmune responses that contribute to ß-cell destruction in T1D, as 
discussed below.
We first found that INS-1 cells express GABAA-R subunits that should confer benzodiazepine sensitiv-
ity and that these cells could produce low levels of GABA. Next, we asked whether three clinically applicable 
BBB-permeable benzodiazepine PAMs, as well as a peripherally restricted non-benzodiazepine PAM, could pro-
mote INS-1 cell proliferation. We observed that two of the four tested PAMs had a significant, albeit low, ability 
to promote INS-1 replication at least one of the dosages tested. This proliferative effect was independent of TSPO.
The PAM’s ability to increase INS-1 proliferation is likely to be mediated by enhancing the effect of endoge-
nous GABA on activation of GABAA-Rs in an autocrine manner. Furthermore, while treatment with a low dose of 
GABA failed to stimulate significantly INS-1 cell proliferation, all of the tested PAMs at a nanomolar level enabled 
low doses of exogenous GABA to induce INS-1 cell proliferation in vitro.
Of the four GABAA-R PAMs that we tested on INS-1 cells, we carried alprazolam’s forward to study its effects 
on human islet cell replication because of alprazolam’s safety profile and a previous observation that alprazolam 
treatment reduced HbA1c levels in diabetics15, as discussed below. We observed that alprazolam (alone) enhanced 
human islet cell replication in vitro, most likely because it acted in conjunction with GABA secreted from ß-cells. 
Indeed, blocking GABA binding to GABAA-Rs with the antagonist bicuculline abrogated the ability of alprazolam 
to enhance islet cell replication. This suggests that ß-cell secreted GABA is involved in ß-cell replication in an 
autocrine manner and that this activity can be enhanced by a GABAA-R PAM. Addition of nifedipine to these 
cultures blocked alprazolam’s pro-mitotic effects, suggesting it enhances GABAA-R-mediated activation of the 
PI3K/Akt pathway3.
In combination, alprazolam and exogenous GABA had a greater ability to promote human islet-cell replica-
tion, and achieved a level of proliferation similar to that of GABA (alone) at ten-fold higher levels. The proliferat-
ing islet cells are likely to be primarily ß-cells because; 1) GABA increases human ß-cell, but not α-cell mass6, 7, 2) 
long-term GABA treatment is needed to promote the transdifferentiation of α-cells to ß-cells7 and such transdif-
ferentiation would not require new DNA synthesis and would therefore not contribute to 3H-thymidine incor-
poration in our assays, and 3) islet δ and PP cells are not known to express GABA-Rs. While the spontaneous 
proliferation of non-ß-cells may have contributed in small part to the proliferation index of islet cells in all the 
in vitro cultures, our experiments with INS-1 cells provide direct evidence of the ability of GABAA-R PAMs to 
enhance endogenous GABA-stimulated ß-cell replication. We are currently conducting in vivo experiments to 
extend our in vitro observations.
A clinical trial conducted in the early 1990’s asked whether alprazolam treatment could help individuals who 
suffered from anxiety and also had poorly controlled T1D or T2D to better manage their diabetes. A group of 
nonanxious individuals with T1D or T2D who had poorly controlled blood glucose levels were also included in 
the study. Surprisingly, treatment with alprazolam, but not placebo, reduced blood HbA1c levels regardless of 
whether the patients suffered from anxiety15. These results were thought to stem from alprazolam’s modulation 
of neurotransmitter and neurohormone release. In light of our findings, it is possible that alprazolam’s beneficial 
effect on HbA1c may have arisen, at least in part, from enhancing the ability of islet GABA to promote ß-cell 
survival, replication and/or the transdifferentiation of α-cells into ß-cells.
We envision several different paths by which our findings could lead to clinical benefits. First, it may be pos-
sible to improve ß-cell mass and function in diabetics using BBB-permeable GABAA-R PAMs at doses below 
those used for CNS indications. Second, because the amount of ß-cell mass following T1D onset is a major factor 
determining the success of interventive therapy, a short-term PAM treatment may help preserve residual ß-cell 
mass and thereby improve the efficacy of interventive therapies. Along this line, GABA treatment enhanced ß-cell 
replication and survival in newly diabetic NOD mice and led to reversal of hyperglycemia3, 7, 17, indicating that 
enhancing GABA-R activity can be beneficial even when little ß-cell mass remains and there is robust ß-cell auto-
reactivity. Those observations are likely to reflect GABA’s ability to promote ß-cell replication/survival and α-cell 
transdifferentiation, as well as to inhibit inflammation (see below). Third, a short-term PAM treatment may help 
reduce ß-cell loss due to hypoxia and stress following islet transplantation, as suggested by the ability of GABA 
treatment to improve ß-cell survival in human islet xenografts4, 6. Finally, immune cells also express GABA-Rs 
and their activation can inhibit proinflammatory Th1, CD8+ and antigen-presenting cell responses3, 5, 17–22, as well 
as promote CD4+ Tregs3, 23. GABA-R activation has been shown to ameliorate disease in mouse models of T1D, 
experimental autoimmune encephalomyelitis, rheumatoid arthritis and T2D3, 5, 17–24. Therefore, GABA released 
from islet ß-cells may locally down-regulate inflammatory islet-infiltrates, and that propensity may be potentiated 
by treatment with a GABAA-R PAM. Furthermore, because the levels of circulating GABA may be insufficient 
to effectively inhibit inflammatory cells in the periphery, combination treatment with low doses of GABA and a 
GABAA-R PAM may suppress peripheral pro-inflammatory responses. Together, our observations suggest that 
GABAA-R PAMs may provide new avenues for safely enhancing ß-cell mass/function and simultaneously helping 
to control inflammatory immune responses that contribute to T1D and T2D pathogenesis.
Methods
Chemicals. Alprazolam, midazolam, clonazepam, PK11195, and bicuculline were purchased from Sigma-
Aldrich. AP-3 was provided by Algiax Pharmaceuticals GmbH. Stock solutions of alprazolam (10 mM in DMSO), 
midazolam (6.25 mM in water), clonazepam (50 mM in ETOH), or AP-3 (50 mM in DMSO) were diluted into 
media to the indicated concentration.
GAD enzymatic activity assay. INS-1 cells and 293 T cells (harvested in growth phase), as well as fresh 
mouse brain and human islets were stored at −80 C until use. The samples were rapidly homogenized into GAD 
www.nature.com/scientificreports/
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activity assay buffer with protease inhibitors. The GAD enzymatic activity within homogenates was assessed using 
a standard CO2 trapping assay (in quadruplicate) as previously described25.
Identification of GABAA-R subunits in INS-1 cells using qRT-PCR. We designed GABAA-R 
subunit-specific primers that spanned introns in genomic DNA. Total RNA was extracted from INS-1 cells using 
Qiagen’s RNeasy Mini Kit and was reversed transcribed into cDNA using ThermoFisher Scientific’s High-Capacity 
RNA-to-cDNA Kit. The presence of different GABAA-R subunit transcripts was assessed using qRT-PCR and the 
Applied Biosystem’s PowerUp SYBR Green Master Mix.
Proliferation assays. INS-1 cell 3H-thymidine incorporation assay: INS-1 cells at 1 × 105/well were treated 
in triplicate with indicated concentrations of individual compounds and cultured in 10% FCS RPMI164 medium 
in the presence of 3H-thymidine (0.3 μCi/well) for 48 hours (an optimal time period). The cells were harvested 
and the levels of 3H-thymidine uptake in individual wells were measured by a scintillation counter.
Islet cell proliferation assay: Fresh human islets were obtained from the Integrated Islet Distribution Program 
and islets (50–75 IEQ/well) were treated in triplicate with the indicated dosage of GABA, together with, or with-
out, the indicated PAM in CMRL medium (0.1% glucose, Gibco) containing 10% human AB-type sera (MP 
Biomedicals, Santa Ana, USA) for 4 days in the presence of 3H thymidine (0.2 mCi/well) and then harvested and 
counted as above.
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium) assay: INS-1 cells at 1 × 105/well were treated 
in quadruplicate with the indicated compounds in 10% FCS RPMI164 medium (phenol–free) for 44 hours. The 
cells were exposed to 20 µl of MTT (20 mg/ml, Sigma) for 4 hours. After the supernatants of cultured cells were 
removed, the resulting formazan in individual wells were dissolved in 100 ml DMSO and measured at absorbance 
of 570/650 nm in a microplate reader.
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